Aclaris is a cash-burning biotech with shrinking revenue, but losses are contained near -$0.15 per share, results mostly beat estimates, and the $8.86 analyst target implies 136.2% upside from $3.75.
Thesis pillars
- Heavy Cash Burn→Stable
- Declining Revenue→Stable
- Losses Contained Beats Estimates→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 26, 2026
Aclaris Therapeutics, Inc. (ACRS) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.96: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule and biologic product candidates for immuno-inflammatory diseases, using its proprietary KINect kinase-discovery platform alongside licensed antibody programs. Its lead assets include... Read more
Sell if holding. Engine safety override at $3.96: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 5.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.50, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: speculative.
About Aclaris Therapeutics, Inc.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics is advancing four clinical-stage immuno-inflammatory product candidates: bosakitug, a monoclonal antibody targeting TSLP with Phase 2 topline data expected in the second half of 2026; ATI-052, a TSLP/IL-4Ra bispecific antibody now in Phase 1b trials for atopic dermatitis and asthma; and the oral ITK/JAK3 inhibitor ATI-2138, which met its primary endpoint in a Phase 2a atopic dermatitis trial in July 2025. The company held $151.4 million in cash and marketable securities as of December 31, 2025, against a $64.9 million net loss for the year.
Aclaris does not intend to commercialize its product candidates alone; its stated strategy is to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for, and commercialize each asset, meaning future revenue depends on striking and executing partnership agreements rather than direct product sales. Both of its lead biologics, bosakitug and ATI-052, are exclusively licensed worldwide (excluding Greater China) from Biosion, Inc., while bosakitug's Greater China rights and development are licensed separately to CTTQ, and the company has licensed its topical JAK inhibitor lepzacitinib's Greater China rights to Pediatrix Therapeutics while still seeking a global partner outside that territory. Aclaris owns no manufacturing facilities and relies entirely on third parties to produce preclinical and clinical drug supply for all of its product candidates.
Show full overview
Aclaris's business model creates a structural dependency most biotechs don't share: because the company explicitly plans to out-license rather than commercialize its own candidates, its eventual revenue hinges not just on clinical trial success but on its ability to negotiate and close partnership agreements on acceptable terms, a step the 10-K flags as a distinct risk on top of ordinary development risk. That dependency is concentrated in a single external licensor, Biosion, which holds the underlying rights to both TSLP-targeting programs, bosakitug and ATI-052, that make up the bulk of the company's near-term clinical catalysts, with topline data across both programs expected through 2026.
See also: Healthcare · Biotechnology
From Aclaris Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Aclaris Therapeutics, Inc.
Latest news
- NEWS Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8 — benzinga Oct 28, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target — benzinga Oct 28, 2026 positive
- NEWS Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug — benzinga Oct 27, 2026 positive
- NEWS Aclaris Therapeutics Prices $50 Million Public Offering — fiscal.ai Oct 27, 2026 negative
- NEWS Aclaris Therapeutics Reports Positive Phase 1b Proof-of-Concept Results for ATI-052 — fiscal.ai Oct 27, 2026 positive
Generated 2026-10-29T11:14:30Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyBiosion10-K Item 1: 'We exclusively license global rights (excluding Mainland China, Macau, Hong Kong and Taiwan ("Greater China")) to bosakitug from Biosion, Inc.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Revenue shrinking — -8.3% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.96: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $3.68. Score 5.0/10, moderate confidence.
Analyst target: $8.78 (+121.7% upside). Prior stop was $3.68. Stop-loss: $3.68.
Concentration risk — Counterparty: Biosion; Quality below floor (2.1 < 4.0).
Aclaris Therapeutics, Inc. trades at a P/E of N/A (forward -5.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover ACRS with a consensus score of 4.3/5. Average price target: $10.
What does Aclaris Therapeutics, Inc. do?Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule and biologic product...
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule and biologic product candidates for immuno-inflammatory diseases, using its proprietary KINect kinase-discovery platform alongside licensed antibody programs. Its lead assets include bosakitug and ATI-052, TSLP-targeting antibodies exclusively licensed from Biosion, and internally discovered ITK/JAK inhibitors ATI-2138 and ATI-9494, none of which are FDA-approved; the company reported a $64.9 million net loss in 2025 and $151.4 million in cash and marketable securities.